2019年ARVO:Tocilizumab显著减少巨细胞动脉炎的发作次数

2019-05-04 不详 网络

根据2019年视觉和眼科学研究协会年会(ARVO)的一项回顾性分析结果,Tocilizumab的治疗与巨细胞动脉炎(GCA)患者的发作次数的显著减少有关。

根据2019年视觉和眼科学研究协会年会(ARVO)的一项回顾性分析结果,Tocilizumab的治疗与巨细胞动脉炎(GCA)患者的发作次数的显著减少有关。GCA是中等血管和大血管的慢性血管炎,患者年龄均大于50岁,平均诊断年龄为72岁。该病很多重要的特征,如前部缺血性视神经病变是由累及主动脉弓一级分支的颅内分支血管炎症引起的。

约翰霍普金斯大学医学院威尔默眼科研究所的Timothy J. McCulley博士说:“Tocilizumab可能是治疗伴有视力相关症状的GCA患者的有效方法,并可能预防新的视觉症状的发生。在60GCA患者中,22例患者(36.6%)在诊断时出现视力障碍。开始使用tocilizumab治疗后,新视觉症状的发生减少,且没有新的永久性视力丧失的报告。


原始出处:

http://www.firstwordpharma.com/node/1638634#axzz5mwpWeWX8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683196, encodeId=a4b21683196f0, content=<a href='/topic/show?id=60f03325e28' target=_blank style='color:#2F92EE;'>#动脉炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33257, encryptionId=60f03325e28, topicName=动脉炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d22a27947071, createdName=xsm927, createdTime=Thu Sep 12 07:15:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912127, encodeId=97ff191212e8a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 17 16:15:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993316, encodeId=13461993316b2, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2804, encryptionId=b2f1280466, topicName=ARVO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 15 05:15:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502250, encodeId=f0b415022500c, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon May 06 09:15:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2019-09-12 xsm927
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683196, encodeId=a4b21683196f0, content=<a href='/topic/show?id=60f03325e28' target=_blank style='color:#2F92EE;'>#动脉炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33257, encryptionId=60f03325e28, topicName=动脉炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d22a27947071, createdName=xsm927, createdTime=Thu Sep 12 07:15:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912127, encodeId=97ff191212e8a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 17 16:15:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993316, encodeId=13461993316b2, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2804, encryptionId=b2f1280466, topicName=ARVO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 15 05:15:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502250, encodeId=f0b415022500c, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon May 06 09:15:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2020-01-17 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1683196, encodeId=a4b21683196f0, content=<a href='/topic/show?id=60f03325e28' target=_blank style='color:#2F92EE;'>#动脉炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33257, encryptionId=60f03325e28, topicName=动脉炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d22a27947071, createdName=xsm927, createdTime=Thu Sep 12 07:15:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912127, encodeId=97ff191212e8a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 17 16:15:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993316, encodeId=13461993316b2, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2804, encryptionId=b2f1280466, topicName=ARVO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 15 05:15:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502250, encodeId=f0b415022500c, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon May 06 09:15:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1683196, encodeId=a4b21683196f0, content=<a href='/topic/show?id=60f03325e28' target=_blank style='color:#2F92EE;'>#动脉炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33257, encryptionId=60f03325e28, topicName=动脉炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d22a27947071, createdName=xsm927, createdTime=Thu Sep 12 07:15:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912127, encodeId=97ff191212e8a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jan 17 16:15:00 CST 2020, time=2020-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993316, encodeId=13461993316b2, content=<a href='/topic/show?id=b2f1280466' target=_blank style='color:#2F92EE;'>#ARVO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2804, encryptionId=b2f1280466, topicName=ARVO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jan 15 05:15:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502250, encodeId=f0b415022500c, content=<a href='/topic/show?id=021d4821096' target=_blank style='color:#2F92EE;'>#巨细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48210, encryptionId=021d4821096, topicName=巨细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11759518880, createdName=wwzzly, createdTime=Mon May 06 09:15:00 CST 2019, time=2019-05-06, status=1, ipAttribution=)]
    2019-05-06 wwzzly

相关资讯

Arthritis Rheumatol:Tocilizumab可有效治疗JIA相关葡萄膜炎

近期有研究称,对于重症幼年特发性关节炎相关的葡萄膜炎、既往常规免疫抑制药物和至少一种抗肿瘤坏死因子剂治疗失败的患者,Tocilizumab治疗是有效的。 研究人员进行了一项多中心研究,纳入了25例重症幼年特发性关节炎相关的葡萄膜炎、既往常规免疫抑制药物和至少一种抗肿瘤坏死因子剂治疗失败的患者,治疗药物包括阿达木单抗(n = 24)、依那西普(n =8)、英夫利昔单抗(n =7)、阿巴西普(n

Lancet:Tocilizumab治疗巨细胞动脉炎的有效性

背景:巨细胞动脉炎是一种免疫介导的大中动脉疾病,常影响50岁以上人群。糖皮质激素治疗是金标准,可预防严重血管并发症,但也与大量的死亡率和发病率相关。托珠单抗(Tocilizumab),一种抗人白介素6(IL-6)受体抗体,可快速反应并缓解巨细胞动脉炎。我们开展了首个随机临床试验研究tocilizumab在新近诊断或复发性巨细胞动脉炎患者中的安全性和有效性。方法:单中心,随机,双盲,安慰剂对照试验,

NEJM: Tocilizumab可有效治疗全身性幼年型特发性关节炎

全身性幼年型特发性关节炎(JIA)是JIA最严重的亚型,治疗选择有限,白介素(IL)-6在全身性JIA中具有致病作用。意大利罗马大学De Benedetti博士等人对此进行了深入研究,他们发现,Tocilizumab治疗严重的持续性全身性JIA有效。不良事件常见,包括感染、中性粒细胞减少和转氨酶水平升高。相关论文发表于国际权威杂志NEJM 2012年12月20日在线版。 研究人员对112例年龄为

Lancet:循证医学发现阻断IL6受体可能用于冠心病防治

近日,国际权威医学期刊《柳叶刀》The Lancet在线刊登了两项国际大规模荟萃分析(meta-analyses)研究成果,在这两篇论文中研究人员发布了令人注目的新数据,证实一种参与炎症信号通路的蛋白——白介素-6受体(IL6R)是冠状动脉心脏病(简称冠心病,CHD)的致病原因。这些研究发现表明靶向特异性炎症机制(例如IL6R介导的信号通路)的药物或许也能有效防治冠心病。当前有一种这样的药物toc

喜讯!FDA授予罗氏抗炎药Actemra/RoActemra第2个突破性药物资格,治疗巨细胞动脉炎(GCA)

瑞士制药巨头罗氏(Roche)抗炎药Actemra/RoActemra(tocilizumab,托珠单抗)近日在美国监管方面传来喜讯。FDA已授予Actemra/RoActemra治疗巨细胞动脉炎(GCA)的突破性药物资格(BTD),这也是该药在美国监管方面获得的第2个突破性药物资格,之前,FDA于2015年6月授予该药治疗系统性硬化症(SSc)的BTD。值得一提的是,此次BTD,也是罗氏自2

Tocilizumab治疗RA有效

来源:医学论坛网   日本一项最新研究表明,在日常临床实践中,tocilizumab对确诊RA患者表现出优良的疗效。该研究论文7月13日在线发表于《风湿病学》(Rheumatology)杂志。   本研究连续纳入使用tocilizumab的232例RA患者,观察52周。患者年龄平均为59.1岁,病程平均为12.4年,28关节疾病活动性评分(DAS28)均值为5.6。尽管62.8%患者曾接受抗肿